Abstract
Recent advances in comprehensive genome analysis have contributed to the discovery of several leukemia-related genes; however, the role of mutated genes in the pathogenesis of leukemia remains unknown. Clustered regularly interspaced short palindromic repeats-associated nuclease 9 (CRISPR-Cas9) technology is a powerful tool for genome-wide editing in both coding and noncoding regions. CRISPR screening has enabled high-throughput validation of gene function in diverse tumor processes, including tumor growth and survival, synthetic lethal interactions, therapeutic resistance, and response to immunotherapy, and is actively used in leukemia research. Herein, we discuss recent advances in CRISPR screening in cancer research, focusing on leukemia, and outline application strategies and prospects for CRISPR screening.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: [Rinsho ketsueki] The Japanese journal of clinical hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
